Cas:22978-61-6 3,5-dichlorobenzenecarboximidamide,hydrochloride manufacturer & supplier

We serve Chemical Name:3,5-dichlorobenzenecarboximidamide,hydrochloride CAS:22978-61-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

3,5-dichlorobenzenecarboximidamide,hydrochloride

Chemical Name:3,5-dichlorobenzenecarboximidamide,hydrochloride
CAS.NO:22978-61-6
Synonyms:3,5-dichlorobenzamidine hydrochloride;BESTIPHARMA 538-443;3,5-dichlorobenzene-1-carboximidamide hydrochloride;3,5-dichlorobenzimidamide hydrochloride;3,5-dichlorobenzenecarboximidamide Hydrochloride
Molecular Formula:C7H7Cl3N2
Molecular Weight:225.50300
HS Code:2925290090

Physical and Chemical Properties:
Melting point:254ºC
Boiling point:296ºC at 760mmHg
Density:N/A
Index of Refraction:
PSA:49.87000
Exact Mass:223.96700
LogP:3.87950

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 3,5-dichlorobenzamidine hydrochloride chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3,5-dichlorobenzenecarboximidamide Hydrochloride physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3,5-dichlorobenzamidine hydrochloride Use and application,3,5-dichlorobenzamidine hydrochloride technical grade,usp/ep/jp grade.


Related News: ��CAR T-cell therapy continues to deliver remarkable outcomes for patients with hematologic malignancies, and next-generation approaches are needed to enable broad and timely patient access and reduce the cost and complexity of therapy,�� said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics. 3,5-dichlorobenzenecarboximidamide,hydrochloride manufacturer ��CAR T-cell therapy continues to deliver remarkable outcomes for patients with hematologic malignancies, and next-generation approaches are needed to enable broad and timely patient access and reduce the cost and complexity of therapy,�� said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics. 3,5-dichlorobenzenecarboximidamide,hydrochloride supplier US citizens who’ve been in other parts of mainland China in the last 14 days will undergo screening at US ports of entry and up to 14 days of self-monitoring. 3,5-dichlorobenzenecarboximidamide,hydrochloride vendor He added that the government raised the travel advice warning to level four, the highest, meaning they’re now advising people not to travel to mainland China. The warning aims to address ��the issue of the human-to-human transmission of the coronavirus.�� 3,5-dichlorobenzenecarboximidamide,hydrochloride factory Optimize the reaction and improve the production process to reduce the production cost. At the same time, strengthen the determination and analysis of impurities to improve product quality.